Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul 02447, Korea.
Department of Pharmacology, College of Medicine, Kyung Hee University, Seoul 02447, Korea.
Chin Med J (Engl). 2017 Aug 20;130(16):1961-1967. doi: 10.4103/0366-6999.211874.
DNA methylation has been suggested as a biomarker for early cancer detection and treatment. Varieties of technologies for detecting DNA methylation have been developed, but they are not sufficiently sensitive for use in diagnostic devices. The aim of this study was to determine the suitability of Raman spectroscopy for label-free detection of methylated DNA.
The methylated promoter regions of cancer-related genes cadherin 1 (CDH1) and retinoic acid receptor beta (RARB) served as target DNA sequences. Based on bisulfite conversion, oligonucleotides of methylated or nonmethylated probes and targets were synthesized for the DNA methylation assay. Principal component analysis with linear discriminant analysis (PCA-DA) was used to discriminate the hybridization between probes and targets (methylated probe and methylated target or nonmethylated probe and nonmethylated target) of CDH1 and RARB from nonhybridization between the probe and targets (methylated probe and nonmethylated target or nonmethylated probe and methylated target).
This study revealed that the CDH1 and RARB oligo sets and their hybridization data could be classified using PCA-DA. The classification results for CDH1 methylated probe + CDH1 methylated target versus CDH1 methylated probe + CDH1 unmethylated target showed sensitivity, specificity, and error rates of 92%, 100%, and 8%, respectively. The classification results for the RARB methylated probe + RARB methylated target versus RARB methylated probe + RARB unmethylated target showed sensitivity, specificity, and error rates of 92%, 93%, and 11%, respectively.
Label-free detection of DNA methylation could be achieved using Raman spectroscopy with discriminant analysis.
DNA 甲基化被认为是早期癌症检测和治疗的生物标志物。已经开发出多种用于检测 DNA 甲基化的技术,但它们的灵敏度不足以用于诊断设备。本研究旨在确定拉曼光谱是否适合用于非标记检测甲基化 DNA。
以癌症相关基因 cadherin 1 (CDH1) 和视黄酸受体 β (RARB) 的甲基化启动子区域作为靶 DNA 序列。基于亚硫酸氢盐转化,合成了甲基化或非甲基化探针和靶标的寡核苷酸,用于 DNA 甲基化检测。主成分分析与线性判别分析(PCA-DA)用于区分 CDH1 和 RARB 中探针与靶标(甲基化探针与甲基化靶标或非甲基化探针与非甲基化靶标)之间的杂交与探针与靶标(甲基化探针与非甲基化靶标或非甲基化探针与甲基化靶标)之间的非杂交。
本研究表明,CDH1 和 RARB 寡核苷酸组及其杂交数据可以使用 PCA-DA 进行分类。CDH1 甲基化探针+CDH1 甲基化靶标与 CDH1 甲基化探针+CDH1 非甲基化靶标相比的分类结果显示,敏感性、特异性和错误率分别为 92%、100%和 8%。RARB 甲基化探针+RARB 甲基化靶标与 RARB 甲基化探针+RARB 非甲基化靶标相比的分类结果显示,敏感性、特异性和错误率分别为 92%、93%和 11%。
使用拉曼光谱和判别分析可以实现 DNA 甲基化的非标记检测。